Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion




Patents and patent applications


Biosimilars under development

Interview with CEO Martin Åmark, October 2023

At Xbrane Biopharma

Press Releases

07 Dec 2023


30 Nov 2023

Xbrane Biopharma releases Interim report for January – September 2023

28 Nov 2023

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2023 on November 30, 2023

23 Nov 2023

Xbrane Biopharma is focusing the development portfolio and introducing a cost-savings scheme

31 Oct 2023

Xbrane Biopharma AB (“Xbrane” or the “Company”) announces changes to the number of shares and votes in the Company.

18 Oct 2023

Xbrane Biopharma presents Nomination Committee

30 Sep 2023

Change of number of shares and votes in Xbrane

08 Sep 2023

Xbrane announces that members of Xbrane’s management team have sold shares for tax purposes.

29 Aug 2023

Xbrane Biopharma releases interim report for January – June 2023